We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Adapttech aim to reduce the number of sessions needed to adjust a prosthetic to it’s owner, making prosthetics more comfortable at a much faster rate. Their technology uses a laser scanner combined wearale sensors to determine where the socket needs adjustments.
days to go: Expired investment: £1,225,000
INSPHERE uses image sensors and Artificial Intelligence (AI) to guide and correct robot positioning during the manufacturing process, ensuring right-first-time production. The company argues that industrial robots are not completely accurate and can experience unplanned downtime that can cost up to £10,000 per minute. INSPHERE asserts that its solution allows factory operators to operate safely with less downtime, and with multiple robot and human operators. The company has developed three products since 2013 which have received recognition in the aerospace and industrial automation sectors. INSPHERE is now launching IONA, a network of sensors that can be permanently deployed in a manufacturing environment to monitor and control industrial robots. IONA, the company points out, uses both hardware and software to correct errors taking into account the robot and its relationship to the workpiece. INSPHERE will use the investment to diversify the reach of IONA across markets.
days to go: Expired investment: £1,149,999
Bodytrak is a wearable technology that monitors physiological activity such as heart rate and core body temperature.  This real time data is analysed using cloud based technology and algorithms to supervisors or commanders so early action can be taken on the event of illness or injury.
days to go: Expired investment: £1,123,119
Tamoco Limited are a provider of online data, creating actionable data and aggregating precise consumer location data. Tamoco provides brands with a method of understanding how audiences behave with speed and accuracy, and delivers an innovative content delivery platform for advertisers. The platform utilises precise location to present content relevant to its audience.     
days to go: Expired investment: £1,050,000
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,048,396
Ancon is designed to detect trace elements of things such as explosives, drugs and chemical weapons in the air. Ancon manufactures equipment and components that are up to 10,000 times more sensitive then anything else on the market.
days to go: Expired investment: £1,043,525
Ancon manufacture equipment and components that detect trace elements of explosives, drugs and chemical weapons in the air. Ancons technology is roughly 10,000 times more sensitive than anything currently on the market.
days to go: Expired investment: £1,043,525
Zentraxa is focused on precision bioengineering to produce peptides with predictable properties tailored towards purpose. The company points out that peptides are amino acids that are the building blocks of certain proteins needed by the skin, like collagen and elastin. It has come out with a synthetic biology platform, Zentide, that designs, produces and tests novel peptides. Zentraxa argues that Zentide can circumvent previously existing bio-design limits imposed by conventional peptide synthesis and produce tailor-made biomaterials for healthcare, personal care and industrial uses. Zentraxa is initially targeting healthcare with its first biomaterial, a debondable adhesive, for use in wound care. The company asserts that the material has other uses such as cosmetics and industrial applications due to its ability to bond strongly while still being easily and painlessly removable. Zentraxa will use the investment to create a portfolio of other biomaterials for licensing to global businesses in the health and industrial sectors via its Zentide platform. 
days to go: Expired investment: £1,040,000
Market Porter is a food-tech platform connecting independant food producers, such as butchers and farm shops, with the consumers. The company are the only food-tech platform which work on a national scale instead of just locally. They source out the best small scale producers with top quality and taste, all delivered straight to your door. 
days to go: Expired investment: £885,000
Aeristech are a hi-tech engineering company with patented electric motor technology. They use forced induction to compress air before entering the engine which allows more fuel to be burnt in the same amount of space and therefore lowers fuel consumption and lowers emissions. 
days to go: Expired investment: £865,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph